Fernández-Ruiz J - Search Results

1

Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology.

Morales P, Whyte LS, Chicharro R, Gómez-Cañas M, Pazos MR, Goya P, Irving AJ, Fernández-Ruiz J, Ross RA, Jagerovic N. Morales P, et al. J Med Chem. 2016 Mar 10;59(5):1840-53. doi: 10.1021/acs.jmedchem.5b01331. Epub 2016 Feb 5. J Med Chem. 2016. PMID: 26789378

2

Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase.

López-Rodríguez ML, Viso A, Ortega-Gutiérrez S, Fowler CJ, Tiger G, de Lago E, Fernández-Ruiz J, Ramos JA. López-Rodríguez ML, et al. J Med Chem. 2003 Apr 10;46(8):1512-22. doi: 10.1021/jm0210818. J Med Chem. 2003. PMID: 12672252

3

Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors.

López-Rodríguez ML, Viso A, Ortega-Gutiérrez S, Fowler CJ, Tiger G, de Lago E, Fernández-Ruiz J, Ramos JA. López-Rodríguez ML, et al. Eur J Med Chem. 2003 Apr;38(4):403-12. doi: 10.1016/s0223-5234(03)00045-x. Eur J Med Chem. 2003. PMID: 12750028

4

Therapeutic potential of the endocannabinoid system in the brain.

Ramos JA, González S, Sagredo O, Gómez-Ruiz M, Fernández-Ruiz J. Ramos JA, et al. Mini Rev Med Chem. 2005 Jul;5(7):609-17. doi: 10.2174/1389557054368817. Mini Rev Med Chem. 2005. PMID: 16026307 Review.

5

Role of CB2 receptors in neuroprotective effects of cannabinoids.

Fernández-Ruiz J, Pazos MR, García-Arencibia M, Sagredo O, Ramos JA. Fernández-Ruiz J, et al. Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S91-6. doi: 10.1016/j.mce.2008.01.001. Epub 2008 Jan 17. Mol Cell Endocrinol. 2008. PMID: 18291574 Review.

6

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, Fernández-Ruiz J. Sagredo O, et al. Glia. 2009 Aug 15;57(11):1154-67. doi: 10.1002/glia.20838. Glia. 2009. PMID: 19115380 Free PMC article.

7

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, Fernández-Ruiz J, Guzmán M, Galve-Roperh I. Palazuelos J, et al. Brain. 2009 Nov;132(Pt 11):3152-64. doi: 10.1093/brain/awp239. Epub 2009 Oct 5. Brain. 2009. PMID: 19805493

8

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.

Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Börner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Díaz-Hernández M, Ruiz C, Sendtner M, Lucas JJ, de Yébenes JG, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Ginés S, Kraus J, Fernández-Ruiz J, Galve-Roperh I, Guzmán M. Blázquez C, et al. Brain. 2011 Jan;134(Pt 1):119-36. doi: 10.1093/brain/awq278. Epub 2010 Oct 7. Brain. 2011. PMID: 20929960

9

Prospects for cannabinoid therapies in basal ganglia disorders.

Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA. Fernández-Ruiz J, et al. Br J Pharmacol. 2011 Aug;163(7):1365-78. doi: 10.1111/j.1476-5381.2011.01365.x. Br J Pharmacol. 2011. PMID: 21545415 Free PMC article. Review.

10

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.

Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J. Sagredo O, et al. J Neurosci Res. 2011 Sep;89(9):1509-18. doi: 10.1002/jnr.22682. Epub 2011 Jun 14. J Neurosci Res. 2011. PMID: 21674569

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

417 results

Search Page